Published 2 days ago • loading... • Updated 16 hours ago

Sanofi buys US biopharma group Blueprint in $9.1 bln deal

Sanofi agreed on Monday, June 2, 2025, in Paris to acquire US-based Blueprint Medicines for approximately $9.1 billion in cash.
Sanofi pursued this deal to add Blueprint's rare immunology drug Ayvakit and bolster its pipeline in systemic mastocytosis and advanced immunology medicines.
Blueprint shareholders will receive $129 per share plus a non-tradeable CVR offering milestone payments tied to the development of BLU-808, a potent oral KIT inhibitor.
Sanofi CEO Paul Hudson said the acquisition is a 'strategic step forward' enhancing Sanofi's transformation into a leading immunology company and complements recent early-stage medicine buys.
The transaction will broaden Sanofi’s immunology portfolio and pipeline, and the company retains substantial capacity for additional acquisitions in this field.

Insights by Ground AI

Does this summary seem wrong?

45 Articles

All

Left

Center

Right

WFMZ

Center

Sanofi announces major purchase amid pledge to up U.S. investments

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.

2 days ago·Pennsylvania, United States

Read Full Article

STAT

Center

Pharmalittle: We're reading about Sanofi buying Blueprint, a Bristol deal with BioNTech and more

Kymera Therapeutics reported that an experimental drug designed to rival Dupixent succeeded in a closely watched early-stage trial

2 days ago·Boston, United States

Read Full Article

biopharmadive.com

Reposted by

PharmaVOICE

Center

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

2 days ago

Read Full Article